# Euan A Ashley

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 225 papers | 12,705 citations | 54 h-index | 109 g-index |
| 252 ext. papers | 16,205 ext. citations | 11.3 avg, IF | 6.62 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 225 | Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting.. *New England Journal of Medicine*, **2022**, | 59.2 | 10 |
| 224 | Causative Variants for Inherited Cardiac Conditions in a Southeast Asian Population Cohort.. *Circulation Genomic and Precision Medicine*, **2022**, CIRCGEN121003536 | 5.2 | |
| 223 | Ultra-Rapid Nanopore Whole Genome Genetic Diagnosis of Dilated Cardiomyopathy in an Adolescent With Cardiogenic Shock.. *Circulation Genomic and Precision Medicine*, **2022**, CIRCGEN121003591 | 5.2 | 1 |
| 222 | A guide for the diagnosis of rare and undiagnosed disease: beyond the exome.. *Genome Medicine*, **2022**, 14, 23 | 14.4 | 3 |
| 221 | High-Throughput Precision Phenotyping of Left Ventricular Hypertrophy With Cardiovascular Deep Learning.. *JAMA Cardiology*, **2022**, | 16.2 | 9 |
| 220 | Accelerated identification of disease-causing variants with ultra-rapid nanopore genome sequencing.. *Nature Biotechnology*, **2022**, | 44.5 | 4 |
| 219 | Designing clinically translatable artificial intelligence systems for high-dimensional medical imaging. *Nature Machine Intelligence*, **2021**, 3, 929-935 | 22.5 | 3 |
| 218 | Mono- and Biallelic Protein-Truncating Variants in Alpha-Actinin 2 Cause Cardiomyopathy Through Distinct Mechanisms. *Circulation Genomic and Precision Medicine*, **2021**, CIRCGEN121003419 | 5.2 | 1 |
| 217 | Comparison of the FRIEND and Wasserman-Hansen Equations in Predicting Outcomes in Heart Failure. *Journal of the American Heart Association*, **2021**, 10, e021246 | 6 | 0 |
| 216 | Deep learning evaluation of biomarkers from echocardiogram videos. *EBioMedicine*, **2021**, 73, 103613 | 8.8 | 1 |
| 215 | Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy. *Journal of the American Heart Association*, **2021**, 10, e019944 | 6 | 2 |
| 214 | Integrated Polygenic Tool Substantially Enhances Coronary Artery Disease Prediction. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003304 | 5.2 | 19 |
| 213 | Detection of a mosaic CDKL5 deletion and inversion by optical genome mapping ends an exhaustive diagnostic odyssey. *Molecular Genetics & Genomic Medicine*, **2021**, 9, e1665 | 2.3 | 1 |
| 212 | SARS-CoV-2 RNAemia predicts clinical deterioration and extrapulmonary complications from COVID-19. *Clinical Infectious Diseases*, **2021**, | 11.6 | 14 |
| 211 | Generation of three induced pluripotent stem cell lines, SCVIi003-A, SCVIi004-A, SCVIi005-A, from patients with ARVD/C caused by heterozygous mutations in the PKP2 gene. *Stem Cell Research*, **2021**, 53, 102284 | 1.6 | 2 |
| 210 | Mulibrey Nanism and the Real Time Use of Genome and Biobank Engines to Inform Clinical Care in an Ultrarare Disease. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003430 | 5.2 | |
| 209 | Time trajectories in the transcriptomic response to exercise - a meta-analysis. *Nature Communications*, **2021**, 12, 3471 | 17.4 | 8 |

| | | | |
|---|---|---|---|
| 208 | Towards precision medicine in heart failure. *Nature Reviews Cardiology*, **2021**, 18, 745-762 | 14.8 | 4 |
| 207 | Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. *Journal of Experimental Medicine*, **2021**, 218, | 16.6 | 34 |
| 206 | Validation of an Integrated Risk Tool, Including Polygenic Risk Score, for Atherosclerotic Cardiovascular Disease in Multiple Ethnicities and Ancestries. *American Journal of Cardiology*, **2021**, 148, 157-164 | 3 | 10 |
| 205 | Smartphone-Based VO2max Measurement With Heart Snapshot in Clinical and Real-world Settings With a Diverse Population: Validation Study. *JMIR MHealth and UHealth*, **2021**, 9, e26006 | 5.5 | 0 |
| 204 | Combining Clinical and Polygenic Risk Improves Stroke Prediction Among Individuals With Atrial Fibrillation. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003168 | 5.2 | 3 |
| 203 | Disease-specific variant pathogenicity prediction significantly improves variant interpretation in inherited cardiac conditions. *Genetics in Medicine*, **2021**, 23, 69-79 | 8.1 | 4 |
| 202 | Graphical analysis for phenome-wide causal discovery in genotyped population-scale biobanks. *Nature Communications*, **2021**, 12, 350 | 17.4 | 1 |
| 201 | Commonalities across computational workflows for uncovering explanatory variants in undiagnosed cases. *Genetics in Medicine*, **2021**, 23, 1075-1085 | 8.1 | 2 |
| 200 | Whole-Transcriptome Profiling of Human Heart Tissues Reveals the Potential Novel Players and Regulatory Networks in Different Cardiomyopathy Subtypes of Heart Failure. *Circulation Genomic and Precision Medicine*, **2021**, 14, e003142 | 5.2 | 2 |
| 199 | Cardiopulmonary Exercise Testing With Echocardiography to Assess Recovery in Patients With Ventricular Assist Devices. *ASAIO Journal*, **2021**, 67, 1134-1138 | 3.6 | 1 |
| 198 | Benchmarking workflows to assess performance and suitability of germline variant calling pipelines in clinical diagnostic assays. *BMC Bioinformatics*, **2021**, 22, 85 | 3.6 | 2 |
| 197 | Combining digital data and artificial intelligence for cardiovascular health. *Cardiovascular Research*, **2021**, 117, e116-e117 | 9.9 | 0 |
| 196 | Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome. *Journal of Allergy and Clinical Immunology*, **2021**, 148, 585-598 | 11.5 | 5 |
| 195 | Phenotypic Expression, Natural History, and Risk Stratification of Cardiomyopathy Caused by Filamin C Truncating Variants. *Circulation*, **2021**, 144, 1600-1611 | 16.7 | 3 |
| 194 | Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy. *European Heart Journal*, **2021**, 42, 3932-3944 | 9.5 | 6 |
| 193 | The genetics of human performance. *Nature Reviews Genetics*, **2021**, | 30.1 | 3 |
| 192 | Clinical utility of genomic sequencing: a measurement toolkit. *Npj Genomic Medicine*, **2020**, 5, 56 | 6.2 | 14 |
| 191 | Molecular Choreography of Acute Exercise. *Cell*, **2020**, 181, 1112-1130.e16 | 56.2 | 96 |

| | | | |
|---|---|---|---|
| 190 | The Medical Genome Initiative: moving whole-genome sequencing for rare disease diagnosis to the clinic. *Genome Medicine*, **2020**, 12, 48 | 14.4 | 17 |
| 189 | Silencing of ameliorates disease phenotypes in human iPSC-cardiomyocytes. *Physiological Genomics* , **2020**, 52, 293-303 | 3.6 | 6 |
| 188 | Stretch-Induced Biased Signaling in Angiotensin II Type 1 and Apelin Receptors for the Mediation of Cardiac Contractility and Hypertrophy. *Frontiers in Physiology*, **2020**, 11, 181 | 4.6 | 8 |
| 187 | Video-based AI for beat-to-beat assessment of cardiac function. *Nature*, **2020**, 580, 252-256 | 50.4 | 123 |
| 186 | Accuracy of Smartphone Camera Applications for Detecting Atrial Fibrillation: A Systematic Review and Meta-analysis. *JAMA Network Open*, **2020**, 3, e202064 | 10.4 | 30 |
| 185 | Variant Interpretation for Dilated Cardiomyopathy: Refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study. *Circulation Genomic and Precision Medicine*, **2020**, 13, e002480 | 5.2 | 27 |
| 184 | Molecular Transducers of Physical Activity Consortium (MoTrPAC): Mapping the Dynamic Responses to Exercise. *Cell*, **2020**, 181, 1464-1474 | 56.2 | 51 |
| 183 | Deep learning interpretation of echocardiograms. *Npj Digital Medicine*, **2020**, 3, 10 | 15.7 | 104 |
| 182 | Classifying Drugs by their Arrhythmogenic Risk Using Machine Learning. *Biophysical Journal*, **2020**, 118, 1165-1176 | 2.9 | 13 |
| 181 | Cardiac Imaging of Aortic Valve Area From 34 287 UK Biobank Participants Reveals Novel Genetic Associations and Shared Genetic Comorbidity With Multiple Disease Phenotypes. *Circulation Genomic and Precision Medicine*, **2020**, 13, e003014 | 5.2 | 1 |
| 180 | Apelin increases atrial conduction velocity, refractoriness, and prevents inducibility of atrial fibrillation. *JCI Insight*, **2020**, 5, | 9.9 | 7 |
| 179 | High-throughput SARS-CoV-2 and host genome sequencing from single nasopharyngeal swabs **2020**, | | 4 |
| 178 | SARS-CoV-2 RNAaemia predicts clinical deterioration and extrapulmonary complications from COVID-19 **2020**, | | 20 |
| 177 | Echocardiographic Assessment of Left Ventricular Remodeling in American Style Footballers. *International Journal of Sports Medicine*, **2020**, 41, 27-35 | 3.6 | 0 |
| 176 | Limitations of Electrocardiography for Detecting Left Ventricular Hypertrophy or Concentric Remodeling in Athletes. *American Journal of Medicine*, **2020**, 133, 123-132.e8 | 2.4 | 3 |
| 175 | Patient-Specific Induced Pluripotent Stem Cells Implicate Intrinsic Impaired Contractility in Hypoplastic Left Heart Syndrome. *Circulation*, **2020**, 142, 1605-1608 | 16.7 | 14 |
| 174 | Impact of the distance from the chest wall to the heart on surface ECG voltage in athletes. *BMJ Open Sport and Exercise Medicine*, **2020**, 6, e000696 | 3.4 | 0 |
| 173 | Multi-task deep learning for cardiac rhythm detection in wearable devices. *Npj Digital Medicine*, **2020**, 3, 116 | 15.7 | 21 |

| | | | |
|---|---|---|---|
| 172 | Spatial and Functional Distribution of Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy. *Circulation Genomic and Precision Medicine*, **2020**, 13, 396-405 | 5.2 | 19 |
| 171 | A novel noninvasive method for remote heart failure monitoring: the EuleriAn video Magnification apPLications In heart Failure studY (AMPLIFY). *Npj Digital Medicine*, **2019**, 2, 80 | 15.7 | 9 |
| 170 | Cardiopulmonary Exercise Testing, Impedance Cardiography, and Reclassification of Risk in Patients Referred for Heart Failure Evaluation. *Journal of Cardiac Failure*, **2019**, 25, 961-968 | 3.3 | 4 |
| 169 | Pathological Overlap of Arrhythmogenic Right Ventricular Cardiomyopathy and Cardiac Sarcoidosis. *Circulation Genomic and Precision Medicine*, **2019**, 12, 452-454 | 5.2 | 1 |
| 168 | Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: the case of hypertrophic cardiomyopathy. *Genome Medicine*, **2019**, 11, 5 | 14.4 | 54 |
| 167 | Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging. *PLoS ONE*, **2019**, 14, e0217612 | 3.7 | 6 |
| 166 | Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure. *Nature Communications*, **2019**, 10, 2760 | 17.4 | 11 |
| 165 | Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. *Nature Medicine*, **2019**, 25, 911-919 | 50.5 | 116 |
| 164 | Targeted Long-Read RNA Sequencing Demonstrates Transcriptional Diversity Driven by Splice-Site Variation in MYBPC3. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002464 | 5.2 | 5 |
| 163 | Comparison of QT Interval Measurement Methods and Correction Formulas in Atrial Fibrillation. *American Journal of Cardiology*, **2019**, 123, 1822-1827 | 3 | 15 |
| 162 | A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis. *Journal of General Internal Medicine*, **2019**, 34, 1058-1062 | 4 | 3 |
| 161 | Rapid Genome Sequencing in the Critically Ill. *Clinical Chemistry*, **2019**, 65, 723-726 | 5.5 | 3 |
| 160 | Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. *Circulation: Heart Failure*, **2019**, 12, e005371 | 7.6 | 51 |
| 159 | Physical activity, sleep and cardiovascular health data for 50,000 individuals from the MyHeart Counts Study. *Scientific Data*, **2019**, 6, 24 | 8.2 | 17 |
| 158 | A toolkit for genetics providers in follow-up of patients with non-diagnostic exome sequencing. *Journal of Genetic Counseling*, **2019**, 28, 213-228 | 2.5 | 4 |
| 157 | Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. *PLoS ONE*, **2019**, 14, e0214250 | 3.7 | 28 |
| 156 | Time based versus strain based myocardial performance indices in hypertrophic cardiomyopathy, the merging role of left atrial strain. *European Heart Journal Cardiovascular Imaging*, **2019**, 20, 334-342 | 4.1 | 9 |
| 155 | Personalized prediction of adverse heart and kidney events using baseline and longitudinal data from SPRINT and ACCORD. *PLoS ONE*, **2019**, 14, e0219728 | 3.7 | 3 |

| | | | |
|---|---|---|---|
| 154 | Approaching Higher Dimension Imaging Data Using Cluster-Based Hierarchical Modeling in Patients with Heart Failure Preserved Ejection Fraction. *Scientific Reports*, **2019**, 9, 10431 | 4.9 | 1 |
| 153 | Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation. *Circulation*, **2019**, 140, 765-778 | 16.7 | 14 |
| 152 | Weakly supervised classification of aortic valve malformations using unlabeled cardiac MRI sequences. *Nature Communications*, **2019**, 10, 3111 | 17.4 | 40 |
| 151 | The effect of digital physical activity interventions on daily step count: a randomised controlled crossover substudy of the MyHeart Counts Cardiovascular Health Study. *The Lancet Digital Health*, **2019**, 1, e344-e352 | 14.4 | 20 |
| 150 | Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing. *Journal of Genetic Counseling*, **2019**, 28, 1107-1118 | 2.5 | 20 |
| 149 | Loss of function, missense, and intronic variants in NOTCH1 confer different risks for left ventricular outflow tract obstructive heart defects in two European cohorts. *Genetic Epidemiology*, **2019**, 43, 215-226 | 2.6 | 12 |
| 148 | A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay. *Circulation*, **2019**, 139, 799-811 | 16.7 | 54 |
| 147 | Athletic Remodeling in Female College Athletes: The "Morganroth Hypothesis" Revisited. *Clinical Journal of Sport Medicine*, **2019**, 29, 224-231 | 3.2 | 13 |
| 146 | A reference equation for maximal aerobic power for treadmill and cycle ergometer exercise testing: Analysis from the FRIEND registry. *European Journal of Preventive Cardiology*, **2018**, 25, 742-750 | 3.9 | 30 |
| 145 | Applying current normative data to prognosis in heart failure: The Fitness Registry and the Importance of Exercise National Database (FRIEND). *International Journal of Cardiology*, **2018**, 263, 75-79 | 3.2 | 8 |
| 144 | Biallelic Mutations in ATP5F1D, which Encodes a Subunit of ATP Synthase, Cause a Metabolic Disorder. *American Journal of Human Genetics*, **2018**, 102, 494-504 | 11 | 44 |
| 143 | Large Q and S waves in lead III on the electrocardiogram distinguish patients with hypertrophic cardiomyopathy from athletes. *Heart*, **2018**, 104, 1871-1877 | 5.1 | 2 |
| 142 | Biological Insights Into Muscular Strength: Genetic Findings in the UK Biobank. *Scientific Reports*, **2018**, 8, 6451 | 4.9 | 42 |
| 141 | Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study. *Nature Communications*, **2018**, 9, 1612 | 17.4 | 61 |
| 140 | Prevalence and Progression of Late Gadolinium Enhancement in Children and Adolescents With Hypertrophic Cardiomyopathy. *Circulation*, **2018**, 138, 782-792 | 16.7 | 40 |
| 139 | A New Approach to Rare Diseases of Children: The Undiagnosed Diseases Network. *Journal of Pediatrics*, **2018**, 196, 291-297.e2 | 3.6 | 12 |
| 138 | Right Ventricular Structure and Function in the Veteran Ultramarathon Runner: Is There Evidence for Chronic Maladaptation?. *Journal of the American Society of Echocardiography*, **2018**, 31, 598-605.e1 | 5.8 | 4 |
| 137 | Long-read genome sequencing identifies causal structural variation in a Mendelian disease. *Genetics in Medicine*, **2018**, 20, 159-163 | 8.1 | 127 |

| | | | |
|---|---|---|---|
| 136 | Incremental value of right heart metrics and exercise performance to well-validated risk scores in dilated cardiomyopathy. *European Heart Journal Cardiovascular Imaging*, **2018**, 19, 916-925 | 4.1 | 6 |
| 135 | Apelin and APJ orchestrate complex tissue-specific control of cardiomyocyte hypertrophy and contractility in the hypertrophy-heart failure transition. *American Journal of Physiology - Heart and Circulatory Physiology*, **2018**, 315, H348-H356 | 5.2 | 19 |
| 134 | Acetaminophen or Tylenol? A Retrospective Analysis of Medication Digital Communication Practices. *Journal of General Internal Medicine*, **2018**, 33, 1218-1220 | 4 | 3 |
| 133 | Artificial Intelligence in Cardiology. *Journal of the American College of Cardiology*, **2018**, 71, 2668-2679 | 15.1 | 373 |
| 132 | Mobile Health Advances in Physical Activity, Fitness, and Atrial Fibrillation: Moving Hearts. *Journal of the American College of Cardiology*, **2018**, 71, 2691-2701 | 15.1 | 59 |
| 131 | Genetic Reduction in Left Ventricular Protein Kinase C-□and Adverse Ventricular Remodeling in Human Subjects. *Circulation Genomic and Precision Medicine*, **2018**, 11, e001901 | 5.2 | 4 |
| 130 | Cardiovascular disease: The rise of the genetic risk score. *PLoS Medicine*, **2018**, 15, e1002546 | 11.6 | 81 |
| 129 | Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease. *New England Journal of Medicine*, **2018**, 379, 2131-2139 | 59.2 | 129 |
| 128 | Incident Atrial Fibrillation Is Associated With MYH7 Sarcomeric Gene Variation in Hypertrophic Cardiomyopathy. *Circulation: Heart Failure*, **2018**, 11, e005191 | 7.6 | 21 |
| 127 | Telomere shortening is a hallmark of genetic cardiomyopathies. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 9276-9281 | 11.5 | 30 |
| 126 | Cardiovascular Precision Medicine in the Genomics Era. *JACC Basic To Translational Science*, **2018**, 3, 313-326 | 3.7 | 27 |
| 125 | Next-Generation Sequencing in Cardiovascular Disease: Present Clinical Applications and the Horizon of Precision Medicine. *Circulation*, **2017**, 135, 406-409 | 16.7 | 17 |
| 124 | The Undiagnosed Diseases Network: Accelerating Discovery about Health and Disease. *American Journal of Human Genetics*, **2017**, 100, 185-192 | 11 | 102 |
| 123 | Orexin: a Missing Link Between Sleep Disorders and Heart Failure?. *Current Heart Failure Reports*, **2017**, 14, 100-105 | 2.8 | 3 |
| 122 | Informed Consent. *New England Journal of Medicine*, **2017**, 376, 856-867 | 59.2 | 113 |
| 121 | Left atrial function and phenotypes in asymmetric hypertrophic cardiomyopathy. *Echocardiography*, **2017**, 34, 843-850 | 1.5 | 5 |
| 120 | Delivering Clinical Grade Sequencing and Genetic Test Interpretation for Cardiovascular Medicine. *Circulation: Cardiovascular Genetics*, **2017**, 10, | | 5 |
| 119 | MARRVEL: Integration of Human and Model Organism Genetic Resources to Facilitate Functional Annotation of the Human Genome. *American Journal of Human Genetics*, **2017**, 100, 843-853 | 11 | 104 |

| | | | |
|---|---|---|---|
| 118 | A Reference Equation for Normal Standards for VO Max: Analysis from the Fitness Registry and the Importance of Exercise National Database (FRIEND Registry). *Progress in Cardiovascular Diseases*, **2017**, 60, 21-29 | 8.5 | 86 |
| 117 | Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2017**, 317, 1349-1357 | 27.4 | 107 |
| 116 | Feasibility of Obtaining Measures of Lifestyle From a Smartphone App: The MyHeart Counts Cardiovascular Health Study. *JAMA Cardiology*, **2017**, 2, 67-76 | 16.2 | 137 |
| 115 | Load-dependent effects of apelin on murine cardiomyocytes. *Progress in Biophysics and Molecular Biology*, **2017**, 130, 333-343 | 4.7 | 14 |
| 114 | Care in Specialized Centers and Data Sharing Increase Agreement in Hypertrophic Cardiomyopathy Genetic Test Interpretation. *Circulation: Cardiovascular Genetics*, **2017**, 10, | | 27 |
| 113 | Effect of lossy compression of quality scores on variant calling. *Briefings in Bioinformatics*, **2017**, 18, 183-194 | 13.4 | 28 |
| 112 | Mind the Gap: Current Challenges and Future State of Heart Failure Care. *Canadian Journal of Cardiology*, **2017**, 33, 1434-1449 | 3.8 | 13 |
| 111 | Contractile reserve and cardiopulmonary exercise parameters in patients with dilated cardiomyopathy, the two dimensions of exercise testing. *Echocardiography*, **2017**, 34, 1179-1186 | 1.5 | 5 |
| 110 | Value of Strain Imaging and Maximal Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2017**, 120, 1203-1208 | 3 | 9 |
| 109 | Accuracy in Wrist-Worn, Sensor-Based Measurements of Heart Rate and Energy Expenditure in a Diverse Cohort. *Journal of Personalized Medicine*, **2017**, 7, | 3.6 | 260 |
| 108 | Impact of a Genetic Risk Score for Coronary Artery Disease on Reducing Cardiovascular Risk: A Pilot Randomized Controlled Study. *Frontiers in Cardiovascular Medicine*, **2017**, 4, 53 | 5.4 | 29 |
| 107 | Towards precision medicine. *Nature Reviews Genetics*, **2016**, 17, 507-22 | 30.1 | 392 |
| 106 | Taming the genome: towards better genetic test interpretation. *Genome Medicine*, **2016**, 8, 70 | 14.4 | 5 |
| 105 | A research roadmap for next-generation sequencing informatics. *Science Translational Medicine*, **2016**, 8, 335ps10 | 17.5 | 29 |
| 104 | Multidimensional structure-function relationships in human cardiac myosin from population-scale genetic variation. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 6701-6 | 11.5 | 68 |
| 103 | Impact of Septal Reduction on Left Atrial Size and Diastole in Hypertrophic Cardiomyopathy. *Echocardiography*, **2016**, 33, 686-94 | 1.5 | 17 |
| 102 | Hypertrophic Cardiomyopathy as a Cause of Sudden Cardiac Death in the Young: A Meta-Analysis. *American Journal of Medicine*, **2016**, 129, 486-496.e2 | 2.4 | 38 |
| 101 | Athlome Project Consortium: a concerted effort to discover genomic and other "omic" markers of athletic performance. *Physiological Genomics*, **2016**, 48, 183-90 | 3.6 | 67 |

| | | | |
|---|---|---|---|
| 100 | Sports genetics moving forward: lessons learned from medical research. *Physiological Genomics*, **2016**, 48, 175-82 | 3.6 | 21 |
| 99 | Redox regulation of vascular remodeling. *Cellular and Molecular Life Sciences*, **2016**, 73, 349-63 | 10.3 | 20 |
| 98 | De Novo and Rare Variants at Multiple Loci Support the Oligogenic Origins of Atrioventricular Septal Heart Defects. *PLoS Genetics*, **2016**, 12, e1005963 | 6 | 67 |
| 97 | Deep Learning Automates the Quantitative Analysis of Individual Cells in Live-Cell Imaging Experiments. *PLoS Computational Biology*, **2016**, 12, e1005177 | 5 | 265 |
| 96 | Alterations in Cardiac Mechanics Following Ultra-Endurance Exercise: Insights from Left and Right Ventricular Area-Deformation Loops. *Journal of the American Society of Echocardiography*, **2016**, 29, 879-887.e1 | 5.8 | 19 |
| 95 | Denoising of Quality Scores for Boosted Inference and Reduced Storage **2016**, 2016, 251-260 | | 2 |
| 94 | Exploratory insights from the right-sided electrocardiogram following prolonged endurance exercise. *European Journal of Sport Science*, **2016**, 16, 1014-22 | 3.9 | 7 |
| 93 | Comparison of left ventricular manual versus automated derived longitudinal strain: implications for clinical practice and research. *International Journal of Cardiovascular Imaging*, **2016**, 32, 429-37 | 2.5 | 22 |
| 92 | Medical implications of technical accuracy in genome sequencing. *Genome Medicine*, **2016**, 8, 24 | 14.4 | 83 |
| 91 | The Undiagnosed Diseases Program--Reply. *JAMA - Journal of the American Medical Association*, **2016**, 315, 1904 | 27.4 | |
| 90 | In Vivo Post-Cardiac Arrest Myocardial Dysfunction Is Supported by Ca2+/Calmodulin-Dependent Protein Kinase II-Mediated Calcium Long-Term Potentiation and Mitigated by Alda-1, an Agonist of Aldehyde Dehydrogenase Type 2. *Circulation*, **2016**, 134, 961-977 | 16.7 | 12 |
| 89 | Early somatic mosaicism is a rare cause of long-QT syndrome. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, 11555-11560 | 11.5 | 30 |
| 88 | Functional assessment and transplantation of the donor heart after circulatory death. *Journal of Heart and Lung Transplantation*, **2016**, 35, 1443-1452 | 5.8 | 118 |
| 87 | Prevalence and prognostic role of right ventricular involvement in stress-induced cardiomyopathy. *Journal of Cardiac Failure*, **2015**, 21, 419-425 | 3.3 | 22 |
| 86 | Computerized Q wave dimensions in athletes and hypertrophic cardiomyopathy patients. *Journal of Electrocardiology*, **2015**, 48, 362-7 | 1.4 | 11 |
| 85 | Long-term outcomes of septal reduction for obstructive hypertrophic cardiomyopathy. *Journal of Cardiology*, **2015**, 66, 57-62 | 3 | 26 |
| 84 | Additive prognostic value of a cardiopulmonary exercise test score in patients with heart failure and intermediate risk. *International Journal of Cardiology*, **2015**, 178, 262-4 | 3.2 | 8 |
| 83 | The precision medicine initiative: a new national effort. *JAMA - Journal of the American Medical Association*, **2015**, 313, 2119-20 | 27.4 | 324 |

| | | | |
|---|---|---|---|
| 82 | Cardiopulmonary responses and prognosis in hypertrophic cardiomyopathy: a potential role for comprehensive noninvasive hemodynamic assessment. *JACC: Heart Failure*, **2015**, 3, 408-418 | 7.9 | 51 |
| 81 | A Rapid, High-Quality, Cost-Effective, Comprehensive and Expandable Targeted Next-Generation Sequencing Assay for Inherited Heart Diseases. *Circulation Research*, **2015**, 117, 603-11 | 15.7 | 27 |
| 80 | The Undiagnosed Diseases Network of the National Institutes of Health: A National Extension. *JAMA - Journal of the American Medical Association*, **2015**, 314, 1797-8 | 27.4 | 68 |
| 79 | Achieving high-sensitivity for clinical applications using augmented exome sequencing. *Genome Medicine*, **2015**, 7, 71 | 14.4 | 41 |
| 78 | Gender differences in ventricular remodeling and function in college athletes, insights from lean body mass scaling and deformation imaging. *American Journal of Cardiology*, **2015**, 116, 1610-6 | 3 | 19 |
| 77 | RNA-Seq identifies novel myocardial gene expression signatures of heart failure. *Genomics*, **2015**, 105, 83-9 | 4.3 | 129 |
| 76 | Personalized preventive medicine: genetics and the response to regular exercise in preventive interventions. *Progress in Cardiovascular Diseases*, **2015**, 57, 337-46 | 8.5 | 47 |
| 75 | Establishing disease causality for a novel gene variant in familial dilated cardiomyopathy using a functional in-vitro assay of regulated thin filaments and human cardiac myosin. *BMC Medical Genetics*, **2015**, 16, 97 | 2.1 | 3 |
| 74 | Sequence to Medical Phenotypes: A Framework for Interpretation of Human Whole Genome DNA Sequence Data. *PLoS Genetics*, **2015**, 11, e1005496 | 6 | 18 |
| 73 | Promise of Precision Medicine--Reply. *JAMA - Journal of the American Medical Association*, **2015**, 314, 1752-3 | 27.4 | |
| 72 | Systems Genomics Identifies a Key Role for Hypocretin/Orexin Receptor-2 in Human Heart Failure. *Journal of the American College of Cardiology*, **2015**, 66, 2522-33 | 15.1 | 22 |
| 71 | Clinical interpretation and implications of whole-genome sequencing. *JAMA - Journal of the American Medical Association*, **2014**, 311, 1035-45 | 27.4 | 333 |
| 70 | A neural network approach to predicting outcomes in heart failure using cardiopulmonary exercise testing. *International Journal of Cardiology*, **2014**, 171, 265-9 | 3.2 | 24 |
| 69 | Molecular diagnosis of long QT syndrome at 10 days of life by rapid whole genome sequencing. *Heart Rhythm*, **2014**, 11, 1707-13 | 6.7 | 37 |
| 68 | A long noncoding RNA protects the heart from pathological hypertrophy. *Nature*, **2014**, 514, 102-106 | 50.4 | 529 |
| 67 | Identification of a new target of miR-16, Vacuolar Protein Sorting 4a. *PLoS ONE*, **2014**, 9, e101509 | 3.7 | 10 |
| 66 | A Balanced Look at the Implications of Genomic (and Other "Omics") Testing for Disease Diagnosis and Clinical Care. *Genes*, **2014**, 5, 748-66 | 4.2 | 6 |
| 65 | Oxido-reductive regulation of vascular remodeling by receptor tyrosine kinase ROS1. *Journal of Clinical Investigation*, **2014**, 124, 5159-74 | 15.9 | 30 |

| | | | |
|---|---|---|---|
| 64 | How does morphology impact on diastolic function in hypertrophic cardiomyopathy? A single centre experience. *BMJ Open*, **2014**, 4, e004814 | 3 | 8 |
| 63 | Clinical phenotype and outcome of hypertrophic cardiomyopathy associated with thin-filament gene mutations. *Journal of the American College of Cardiology*, **2014**, 64, 2589-2600 | 15.1 | 69 |
| 62 | Patterns and prognosis of all components of the J-wave pattern in multiethnic athletes and ambulatory patients. *American Heart Journal*, **2014**, 167, 259-66 | 4.9 | 31 |
| 61 | Latent obstruction and left atrial size are predictors of clinical deterioration leading to septal reduction in hypertrophic cardiomyopathy. *Journal of Cardiac Failure*, **2014**, 20, 236-43 | 3.3 | 8 |
| 60 | Prevalence and clinical correlates of right ventricular dysfunction in patients with hypertrophic cardiomyopathy. *American Journal of Cardiology*, **2014**, 113, 361-7 | 3 | 41 |
| 59 | Cardiopulmonary and noninvasive hemodynamic responses to exercise predict outcomes in heart failure. *Journal of Cardiac Failure*, **2013**, 19, 101-7 | 3.3 | 17 |
| 58 | Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. *Cell Stem Cell*, **2013**, 12, 101-13 | 18 | 449 |
| 57 | Effects of respiratory exchange ratio on the prognostic value of peak oxygen consumption and ventilatory efficiency in patients with systolic heart failure. *JACC: Heart Failure*, **2013**, 1, 427-32 | 7.9 | 34 |
| 56 | A clinical approach to inherited hypertrophy: the use of family history in diagnosis, risk assessment, and management. *Circulation: Cardiovascular Genetics*, **2013**, 6, 118-31 | | 19 |
| 55 | APJ acts as a dual receptor in cardiac hypertrophy. *Nature*, **2012**, 488, 394-8 | 50.4 | 166 |
| 54 | Personal omics profiling reveals dynamic molecular and medical phenotypes. *Cell*, **2012**, 148, 1293-307 | 56.2 | 921 |
| 53 | Cell-intrinsic functional effects of the cardiac myosin Arg-403-Gln mutation in familial hypertrophic cardiomyopathy. *Biophysical Journal*, **2012**, 102, 2782-90 | 2.9 | 16 |
| 52 | Personalized medicine: hope or hype?. *European Heart Journal*, **2012**, 33, 1564-70 | 9.5 | 51 |
| 51 | Randomized trial of personal genomics for preventive cardiology: design and challenges. *Circulation: Cardiovascular Genetics*, **2012**, 5, 368-76 | | 23 |
| 50 | Systems-based approaches to cardiovascular biomarker discovery. *Circulation: Cardiovascular Genetics*, **2012**, 5, 360-7 | | 30 |
| 49 | Genetics and cardiovascular disease: a policy statement from the American Heart Association. *Circulation*, **2012**, 126, 142-57 | 16.7 | 64 |
| 48 | Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. *Science Translational Medicine*, **2012**, 4, 130ra47 | 17.5 | 497 |
| 47 | DNA sequencing: clinical applications of new DNA sequencing technologies. *Circulation*, **2012**, 125, 931-44 | 16.7 | 57 |

| | | | |
|---|---|---|---|
| 46 | A public resource facilitating clinical use of genomes. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 11920-7 | 11.5 | 154 |
| 45 | Cardiac structural and sarcomere genes associated with cardiomyopathy exhibit marked intolerance of genetic variation. *Circulation: Cardiovascular Genetics*, **2012**, 5, 602-10 | | 45 |
| 44 | Apelin enhances directed cardiac differentiation of mouse and human embryonic stem cells. *PLoS ONE*, **2012**, 7, e38328 | 3.7 | 33 |
| 43 | Performance comparison of whole-genome sequencing platforms. *Nature Biotechnology*, **2011**, 30, 78-82 | 44.5 | 241 |
| 42 | Genetic analysis in cardiovascular disease: a clinical perspective. *Cardiology in Review*, **2011**, 19, 81-9 | 3.2 | 10 |
| 41 | Systems biology of heart failure, challenges and hopes. *Current Opinion in Cardiology*, **2011**, 26, 314-21 | 2.1 | 12 |
| 40 | Personalized Medicine and Cardiovascular Disease: From Genome to Bedside. *Current Cardiovascular Risk Reports*, **2011**, 5, 542-551 | 0.9 | 1 |
| 39 | Phased whole-genome genetic risk in a family quartet using a major allele reference sequence. *PLoS Genetics*, **2011**, 7, e1002280 | 6 | 112 |
| 38 | Gene coexpression network topology of cardiac development, hypertrophy, and failure. *Circulation: Cardiovascular Genetics*, **2011**, 4, 26-35 | | 73 |
| 37 | Chromatin regulation by Brg1 underlies heart muscle development and disease. *Nature*, **2010**, 466, 62-7 | 50.4 | 355 |
| 36 | Clinical assessment incorporating a personal genome. *Lancet, The*, **2010**, 375, 1525-35 | 40 | 565 |
| 35 | Challenges in the clinical application of whole-genome sequencing. *Lancet, The*, **2010**, 375, 1749-51 | 40 | 183 |
| 34 | Drug discovery in a multidimensional world: systems, patterns, and networks. *Journal of Cardiovascular Translational Research*, **2010**, 3, 438-47 | 3.3 | 50 |
| 33 | Aldehyde dehydrogenase activator attenuates diabetic cardiomyopathy; a role in improving the quality of resident cardiac stem cells?. *FASEB Journal*, **2010**, 24, 572.3 | 0.9 | 4 |
| 32 | Endogenous regulation of cardiovascular function by apelin-APJ. *American Journal of Physiology - Heart and Circulatory Physiology*, **2009**, 297, H1904-13 | 5.2 | 136 |
| 31 | Apelin prevents aortic aneurysm formation by inhibiting macrophage inflammation. *American Journal of Physiology - Heart and Circulatory Physiology*, **2009**, 296, H1329-35 | 5.2 | 114 |
| 30 | A new era in clinical genetic testing for hypertrophic cardiomyopathy. *Journal of Cardiovascular Translational Research*, **2009**, 2, 381-91 | 3.3 | 21 |
| 29 | Mechanisms of exercise intolerance in patients with hypertrophic cardiomyopathy. *American Heart Journal*, **2009**, 158, e27-34 | 4.9 | 22 |

| | | | |
|---|---|---|---|
| 28 | Pharmacogenetics of heart failure: evidence, opportunities, and challenges for cardiovascular pharmacogenomics. *Journal of Cardiovascular Translational Research*, **2008**, 1, 25-36 | 3.3 | 3 |
| 27 | Genetics of arrhythmia: disease pathways beyond ion channels. *Journal of Cardiovascular Translational Research*, **2008**, 1, 155-65 | 3.3 | 4 |
| 26 | Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. *Journal of Clinical Investigation*, **2008**, 118, 3343-54 | 15.9 | 214 |
| 25 | Emerging role of the apelin system in cardiovascular homeostasis. *Biomarkers in Medicine*, **2007**, 1, 37-43 | 2.3 | 4 |
| 24 | Frontiers in nephrology: genomic approaches to understanding the molecular basis of atherosclerosis. *Journal of the American Society of Nephrology: JASN*, **2007**, 18, 2853-62 | 12.7 | 2 |
| 23 | Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. *European Journal of Heart Failure*, **2006**, 8, 355-60 | 12.3 | 147 |
| 22 | Network analysis of human in-stent restenosis. *Circulation*, **2006**, 114, 2644-54 | 16.7 | 56 |
| 21 | Perioperative cardiac risk: pathophysiology, assessment and management. *Expert Review of Cardiovascular Therapy*, **2006**, 4, 731-43 | 2.5 | 2 |
| 20 | Angiotensin-converting enzyme genotype predicts cardiac and autonomic responses to prolonged exercise. *Journal of the American College of Cardiology*, **2006**, 48, 523-31 | 15.1 | 38 |
| 19 | Preoperative cardiac evaluation: mechanisms, assessment, and reduction of risk. *Thoracic Surgery Clinics*, **2005**, 15, 263-75 | 3.1 | 10 |
| 18 | Pathway analysis of coronary atherosclerosis. *Physiological Genomics*, **2005**, 23, 103-18 | 3.6 | 136 |
| 17 | The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. *Cardiovascular Research*, **2005**, 65, 73-82 | 9.9 | 253 |
| 16 | Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. *Physiological Genomics*, **2005**, 22, 213-26 | 3.6 | 67 |
| 15 | Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. *Circulation*, **2003**, 108, 1432-9 | 16.7 | 276 |
| 14 | Diagnosing coronary artery disease in diabetic patients. *Diabetes/Metabolism Research and Reviews*, **2002**, 18, 201-8 | 7.5 | 12 |
| 13 | Cardiac nitric oxide synthase 1 regulates basal and beta-adrenergic contractility in murine ventricular myocytes. *Circulation*, **2002**, 105, 3011-6 | 16.7 | 145 |
| 12 | Exercise testing scores as an example of better decisions through science. *Medicine and Science in Sports and Exercise*, **2002**, 34, 1391-8 | 1.2 | 15 |
| 11 | Exercise testing in clinical medicine. *Lancet, The*, **2000**, 356, 1592-7 | 40 | 119 |

| | | |
|---|---|---|
| 10 | Quantitative approaches to variant classification increase the yield and precision of genetic testing in Mendelian diseases: The case of hypertrophic cardiomyopathy | 1 |
| 9 | The Next Generation Precision Medical Record - A Framework for Integrating Genomes and Wearable Sensors with Medical Records | 3 |
| 8 | A precision metric for clinical genome sequencing | 4 |
| 7 | Combining clinical and polygenic risk improves stroke prediction among individuals with atrial fibrillation | 2 |
| 6 | Heart Snapshot: a broadly validated smartphone measure of VO2max for collection of real world data | 1 |
| 5 | Mono- and bi-allelic protein truncating variants in alpha-actinin 2 cause cardiomyopathy through distinct mechanisms | 1 |
| 4 | Constraint-based analysis for causal discovery in population-based biobanks | 2 |
| 3 | Multimodal deep learning enhances diagnostic precision in left ventricular hypertrophy | 1 |
| 2 | Cell-specific chromatin landscape of human coronary artery resolves regulatory mechanisms of disease risk | 1 |
| 1 | Deep Learning Prediction of Biomarkers from Echocardiogram Videos | 4 |